| Deleyrolle, Phuong |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
NCT03671889: ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | N/A | 150 | US | Blood Brain Barrier (BBB) Disruption, ExAblate Neuro | InSightec | Alzheimer Disease | 12/25 | 12/25 | | |
| Woodworth, Graeme F |
NCT05317858: Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets |
|
|
| Recruiting | 3 | 20 | Canada, US, RoW | Blood Brain Barrier Disruption - Oncology, Exablate BBBD, Pembrolizumab | InSightec | Brain Tumor | 06/24 | 12/24 | | |
NCT04417088: Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy |
|
|
| Active, not recruiting | 1/2 | 30 | US | Carboplatin, Exablate BBBD, Exablate Neuro | InSightec | Recurrent Glioblastoma | 12/23 | 07/24 | | |
NCT03551249: Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption |
|
|
| Completed | N/A | 20 | US | Focused ultrasound (FUS), ExAblate, Type 2 | InSightec | Glioma, Glioblastoma | 12/23 | 12/23 | | |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
| Henry, Kaitlyn |
NCT05317858: Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets |
|
|
| Recruiting | 3 | 20 | Canada, US, RoW | Blood Brain Barrier Disruption - Oncology, Exablate BBBD, Pembrolizumab | InSightec | Brain Tumor | 06/24 | 12/24 | | |
| Terminated | 2 | 1 | US | Pioglitazone 15mg | University of Maryland, Baltimore, Nico Corporation | Intracerebral Haemorrhage, Intraventricular | 09/24 | 09/24 | | |
NCT04417088: Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy |
|
|
| Active, not recruiting | 1/2 | 30 | US | Carboplatin, Exablate BBBD, Exablate Neuro | InSightec | Recurrent Glioblastoma | 12/23 | 07/24 | | |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
NCT04579692: MR Guided Focused Ultrasound (FUS) for the Treatment of Trigeminal Neuralgia |
|
|
| Recruiting | N/A | 10 | US | ExAblate Transcranial treatment, The ExAblate® MR guided focused ultrasound system | University of Maryland, Baltimore, Focused Ultrasound Foundation, InSightec | Trigeminal Neuralgia | 06/25 | 06/25 | | |
| Recruiting | N/A | 10 | US | ExAblate Transcranial treatment, The ExAblate® MR guided focused ultrasound system | University of Maryland, Baltimore, Focused Ultrasound Foundation, InSightec | Task-Specific Focal Dystonia | 06/27 | 06/28 | | |
WEB PAS, NCT04839705: Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device |
|
|
| Recruiting | N/A | 180 | US | WEB | Microvention-Terumo, Inc. | Wide Neck Bifurcation Intracranial Aneurysms | 12/25 | 12/29 | | |
NCT05539196: A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications |
|
|
| Recruiting | N/A | 60 | Japan, US | Exablate Pallidotomy, Unilateral | InSightec | Movement Disorders, Neurology, Parkinsons Disease | 07/29 | 07/29 | | |
NCT05409989: MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study |
|
|
| Recruiting | N/A | 154 | US | FRED™ X™, Flow Re-Direction Endoluminal Device X | Microvention-Terumo, Inc. | Intracranial Aneurysm | 09/29 | 11/29 | | |
| Santana, Daylen |
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects |
|
|
| Recruiting | 1/2 | 98 | US | VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine | VBI Vaccines Inc. | Glioblastoma Multiforme | 07/25 | 08/25 | | |
TUTOR, NCT05553522: Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer |
|
|
| Recruiting | 1 | 40 | US | Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine | Baptist Health South Florida, Pfizer | Brain Metastases, HER2-positive Breast Cancer | 02/28 | 02/29 | | |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
| Hilliard, Justin |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
NCT03671889: ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | N/A | 150 | US | Blood Brain Barrier (BBB) Disruption, ExAblate Neuro | InSightec | Alzheimer Disease | 12/25 | 12/25 | | |
